公开(公告)号：US20240408166A1

公开(公告)日：2024-12-12

申请号：US18814073

申请日：2024-08-23

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K38/04 ,  A61K35/12 ,  A61K35/17 ,  A61K39/00 ,  A61K51/10 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/68

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

公开(公告)号：US20240374640A1

公开(公告)日：2024-11-14

申请号：US18599838

申请日：2024-03-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240358756A1

公开(公告)日：2024-10-31

申请号：US18599924

申请日：2024-03-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/4748 ,  C12N5/0636

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240299455A1

公开(公告)日：2024-09-12

申请号：US18599860

申请日：2024-03-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/4748 ,  C12N5/0636

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240269184A1

公开(公告)日：2024-08-15

申请号：US18606764

申请日：2024-03-15

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/4748 ,  C12N5/0636

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240166717A1

公开(公告)日：2024-05-23

申请号：US18433940

申请日：2024-02-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240166713A1

公开(公告)日：2024-05-23

申请号：US18433894

申请日：2024-02-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  A61K38/00 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00 ,  C07K2319/30

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240158460A1

公开(公告)日：2024-05-16

申请号：US18421968

申请日：2024-01-24

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00 ,  C07K2319/30

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240083969A1

公开(公告)日：2024-03-14

申请号：US18321820

申请日：2023-05-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH ,  Gisela SCHIMMACK ,  Michael ROEMER

IPC: C07K14/725 ,  A61K9/19 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/574 ,  G16B25/10

CPC classification number: C07K14/7051 ,  A61K9/19 ,  A61K35/17 ,  A61K39/001111 ,  A61P35/00 ,  C07K14/70539 ,  C07K16/2809 ,  C07K16/2833 ,  C12N5/0638 ,  C12N15/115 ,  G01N33/57492 ,  G16B25/10 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240067697A1

公开(公告)日：2024-02-29

申请号：US18489600

申请日：2023-10-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO:1 to SEQ ID NO:113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.